JP2016506398A5 - - Google Patents

Download PDF

Info

Publication number
JP2016506398A5
JP2016506398A5 JP2015548006A JP2015548006A JP2016506398A5 JP 2016506398 A5 JP2016506398 A5 JP 2016506398A5 JP 2015548006 A JP2015548006 A JP 2015548006A JP 2015548006 A JP2015548006 A JP 2015548006A JP 2016506398 A5 JP2016506398 A5 JP 2016506398A5
Authority
JP
Japan
Prior art keywords
agent
use according
antipruritic
administered
pruritus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015548006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506398A (ja
Filing date
Publication date
Priority claimed from US13/715,625 external-priority patent/US8637538B1/en
Application filed filed Critical
Priority claimed from PCT/US2013/075096 external-priority patent/WO2014093871A1/en
Publication of JP2016506398A publication Critical patent/JP2016506398A/ja
Publication of JP2016506398A5 publication Critical patent/JP2016506398A5/ja
Pending legal-status Critical Current

Links

JP2015548006A 2012-12-14 2013-12-13 そう痒の処置法 Pending JP2016506398A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261737488P 2012-12-14 2012-12-14
US61/737,488 2012-12-14
US13/715,625 US8637538B1 (en) 2012-12-14 2012-12-14 Methods for treatment of pruritis
US13/715,625 2012-12-14
PCT/US2013/075096 WO2014093871A1 (en) 2012-12-14 2013-12-13 Methods for treating pruritus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019071738A Division JP6823857B2 (ja) 2012-12-14 2019-04-04 抗そう痒剤

Publications (2)

Publication Number Publication Date
JP2016506398A JP2016506398A (ja) 2016-03-03
JP2016506398A5 true JP2016506398A5 (enExample) 2017-01-26

Family

ID=50935003

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015548006A Pending JP2016506398A (ja) 2012-12-14 2013-12-13 そう痒の処置法
JP2019071738A Active JP6823857B2 (ja) 2012-12-14 2019-04-04 抗そう痒剤
JP2020179395A Active JP7072280B2 (ja) 2012-12-14 2020-10-27 抗そう痒剤
JP2022072885A Pending JP2022105095A (ja) 2012-12-14 2022-04-27 抗そう痒剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019071738A Active JP6823857B2 (ja) 2012-12-14 2019-04-04 抗そう痒剤
JP2020179395A Active JP7072280B2 (ja) 2012-12-14 2020-10-27 抗そう痒剤
JP2022072885A Pending JP2022105095A (ja) 2012-12-14 2022-04-27 抗そう痒剤

Country Status (13)

Country Link
EP (1) EP2931279B1 (enExample)
JP (4) JP2016506398A (enExample)
KR (3) KR20220044385A (enExample)
CN (2) CN104981246A (enExample)
AU (2) AU2013359017B2 (enExample)
BR (1) BR112015013984A2 (enExample)
CA (1) CA2892393C (enExample)
ES (1) ES2984559T3 (enExample)
MX (1) MX2015007518A (enExample)
NZ (1) NZ708371A (enExample)
RU (1) RU2015128265A (enExample)
WO (1) WO2014093871A1 (enExample)
ZA (2) ZA201504229B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
KR20220044385A (ko) * 2012-12-14 2022-04-07 트레비 테라퓨틱스, 인코포레이티드 소양증을 치료하는 방법
WO2015192071A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
TW201725041A (zh) * 2016-01-04 2017-07-16 懷特生技新藥股份有限公司 治療皮膚癢之醫藥組合物
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
US20180008592A1 (en) * 2016-03-21 2018-01-11 Trevi Therapeutics, Inc. Treatment of uremic pruritus
AU2017350852A1 (en) * 2016-10-25 2019-04-11 Trevi Therapeutics, Inc. Treatment of prurigo nodularis
JP7390695B2 (ja) * 2017-02-03 2023-12-04 株式会社東洋新薬 錠剤及び錠剤の製造方法
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ331001A (en) * 1996-11-25 2000-05-26 Toray Industries Use of an opiate K receptor agonist as an antipruritic
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
LT2425824T (lt) * 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
EP1763349A2 (en) * 2004-06-03 2007-03-21 Jonathan J. Burbaum Pharmaceutical compositions for the treatment of pruritus
PT1931315E (pt) * 2005-08-24 2014-01-03 Endo Pharmaceuticals Inc Formulações de libertação sustentada de nalbufina
US8394812B2 (en) * 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
KR20220044385A (ko) * 2012-12-14 2022-04-07 트레비 테라퓨틱스, 인코포레이티드 소양증을 치료하는 방법

Similar Documents

Publication Publication Date Title
JP2016506398A5 (enExample)
JP2017517553A5 (enExample)
RU2015128265A (ru) Способы лечения зуда
Lee et al. The uses of naltrexone in dermatologic conditions
RU2017101102A (ru) Способы лечения зуда
Prommer et al. Management of pain in the elderly at the end of life
AU2016371598B2 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
BRPI0115910B8 (pt) medicamento compreendendo 5-[(r)-2-(5,6-dietil-indan-2ilamino)-1-hidróxi-etil]-8-hidróxi-1h-quinolin-2-ona e corticóides para o tratamento de doencas inflamatórias ou obstrutivas das vias aéreas
JP2012502103A5 (enExample)
JP2018521047A (ja) 掻痒の治療
CA3224094A1 (en) Use of tricyclic heteroaryl-containing compound
US20170216277A1 (en) Therapeutic use of nalbuphine without aquaretic effects
Partownavid et al. Sugammadex: a comprehensive review of the published human science, including renal studies
WO2006060731A3 (en) Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
Miyazaki et al. Topical morphine gel for pain management in head and neck cancer patients
JP2019509309A5 (enExample)
JP2019532112A5 (ja) 結節性痒疹を治療するための抗掻痒剤
JP2019531286A5 (enExample)
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
CN104546928A (zh) 一种治疗小儿尿布疹的中药组合物及其制备方法
RU2013105513A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
JP2023184678A (ja) 皮膚線維症を処置するための組成物および方法
ITMI20080798A1 (it) Composizione a rilascio modificato a base di doxofillina
MX2007012052A (es) Composiciones y sales dermatologicas para el tratamiento de enfermedades dermatologicas.
Pathania et al. Rivaroxaban induced necrolytic acral erythema